Compass Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Misses Expectations By $0.61 EPS
by Danessa Lincoln · The Markets DailyCompass Pathways (NASDAQ:CMPS – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.61), FiscalAI reports.
Compass Pathways Price Performance
CMPS opened at $5.34 on Tuesday. The stock has a 50-day moving average price of $6.82 and a 200-day moving average price of $6.30. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. Compass Pathways has a 1 year low of $2.25 and a 1 year high of $8.90. The firm has a market cap of $512.73 million, a PE ratio of -1.96 and a beta of 1.90.
Analyst Upgrades and Downgrades
CMPS has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Compass Point set a $15.00 price objective on shares of Compass Pathways in a report on Thursday, February 12th. Morgan Stanley boosted their price objective on Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Royal Bank Of Canada lifted their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, HC Wainwright raised their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.13.
View Our Latest Analysis on CMPS
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways in the fourth quarter valued at about $38,000. Advisory Services Network LLC purchased a new stake in shares of Compass Pathways during the third quarter worth about $41,000. Northeast Financial Consultants Inc acquired a new position in shares of Compass Pathways during the second quarter valued at about $59,000. MML Investors Services LLC purchased a new position in shares of Compass Pathways in the 4th quarter valued at approximately $69,000. Finally, Raymond James Financial Inc. boosted its stake in Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.
Compass Pathways Company Profile
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.